^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RET overexpression

    i
    Other names: RET, Ret Proto-Oncogene, Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret, Cadherin-Related Family Member 16, Rearranged During Transfection, RET Receptor Tyrosine Kinase, Cadherin Family Member 12, Proto-Oncogene C-Ret, CDHF12, CDHR16, PTC, Ret Proto-Oncogene (Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease), Multiple Endocrine Neoplasia And Medullary Thyroid Carcinoma 1, Hirschsprung Disease 1, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, MTC1
    Entrez ID:
    5979
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions. (IASLC-WCLC 2023)
    cMET was frequently expressed on the membrane in RET+ aNSCLC, deserving further exploration for novel treatment strategies. cMET expression did not seem to correlate with biological features or to response to RETi.
    Clinical • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • KIF5B (Kinesin Family Member 5B)
    |
    PD-L1 expression • MET amplification • RET fusion • MET mutation • MET expression • RET overexpression
    over1year
    Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC. (ASCO 2023)
    In this largest-ever retrospective cohort of NSCLC patients with SWI/SNF mutations, SMARCA4mt is the only SWI/SNF alteration broadly associated with worse survival. SMARCA4mt is associated with particularly short survival in KRASmt tumors. These data suggest underlying biology which may inform further investigation and therapeutic development.
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • STK11 (Serine/threonine kinase 11) • ARID1A (AT-rich interaction domain 1A) • KEAP1 (Kelch Like ECH Associated Protein 1) • NRG1 (Neuregulin 1) • PBRM1 (Polybromo 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • ARID2 (AT-Rich Interaction Domain 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    HER-2 amplification • NTRK1 fusion • ALK fusion • ROS1 fusion • NRG1 fusion • RET overexpression
    |
    MI Tumor Seek™
    almost2years
    RET overexpression is frequent in lung neuroendocrine tumors (NET) and associates with response to RET tyrosine kinase inhibitors (RET TKIs) in NET cell lines (AACR 2023)
    Overexpression of RET is frequent in lung tumors with neuroendocrine features (LCNEC, SCLC). Selpercatinib and Pralsetinib show antitumor activity in lung NETs cells expressing high levels of wt-RET.
    Preclinical
    |
    RET (Ret Proto-Oncogene)
    |
    RET fusion • RET mutation • RET overexpression • RET expression • RET positive
    |
    Retevmo (selpercatinib) • Gavreto (pralsetinib)
    2years
    Reversing "Flip-Flop" Phenomenon of 131I and Glucose Avidity in RET-Fusion Positive Radioiodine-Refractory Thyroid Cancer Lesions After Treatment of Pralsetinib. (PubMed, Clin Nucl Med)
    Reduced FDG avidity of those lesions and decreased serum antithyroglobulin antibody titer were also noticed. This case illustrated successfully reinduced 131I avidity in papillary thyroid cancer through redifferentiation with target therapy to suppress tumor RET overexpression.
    Journal
    |
    RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6)
    |
    RET fusion • CCDC6-RET fusion • RET overexpression • RET positive
    |
    Gavreto (pralsetinib)
    over2years
    Large scale mRNA analysis in lung cancer patients reveals frequent high expression of ROS1 and RET not associated with gene fusions (EACR 2022)
    In contrast, the majority of patients with very high ROS1 or RET mRNA levels are fusion negative. Preclinical research is being conducted to determine the clinical relevance of this finding.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK positive • RET fusion • ALK fusion • ALK mutation • ROS1 fusion • ROS1 positive • RET overexpression • RET expression
    over2years
    Aberrant RET expression impacts on normal mammary gland post-lactation transition enhancing cancer potential. (PubMed, Dis Model Mech)
    Using the Ret/MTB doxycycline-inducible mouse transgenic system, we show that sustained expression of RET in the mammary epithelium during the post-lactation transition to involution is accompanied by alterations in tissue remodeling and an enhancement of cancer potential...Furthermore, we show that abnormal RET overexpression during lactation promotes factors that prime involution, including premature activation of Stat3 signaling and, using RNA-seq, an acute-phase inflammatory signature. Our results demonstrate that RET overexpression negatively affects the normal post-lactation transition.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET overexpression • RET expression
    almost3years
    Circ-ITCH overexpression promoted cell proliferation and migration in Hirschsprung disease through miR-146b-5p/RET axis. (PubMed, Pediatr Res)
    The expressions of Circ-ITCH and RET were markedly reduced in HSCR, while miR-146b-5p expression was increased in HSCR. Circ-ITCH overexpression enhanced the proliferative and migratory abilities of SH-SY5Y and 293T cells. Circ-ITCH negatively regulated miR-146b-5p expression.
    Journal
    |
    RET (Ret Proto-Oncogene) • MIR146B (MicroRNA 146b) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    |
    RET overexpression • RET expression
    almost3years
    Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma. (PubMed, Biomolecules)
    At variance, the RET gene, and in particular the RET51 isoform, is expressed higher in RET mutated cases. On the basis of these results we can hypothesize that the overexpression of RET, and in particular of RET51, could potentiate the transforming activity of mutated RET, making these cases more aggressive.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation • RET overexpression • RET expression
    3years
    RET signalling provides tumorigenic mechanism and tissue specificity for AIP-related somatotrophinomas. (PubMed, Oncogene)
    Somatotroph adenomas from patients with or without AIP mutation abundantly express GDNF, but AIP-mutated tissues have less CDKN2A-ARF expression. Our findings explain the tissue-specific mechanism of AIP-induced somatotrophinomas and provide a previously unknown tumorigenic mechanism, opening treatment avenues for AIP-related tumours.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • IGF1 (Insulin-like growth factor 1) • CASP3 (Caspase 3)
    |
    RET mutation • RET overexpression • IGF1 elevation • RET expression